Boehringer Ingelheim agreed to license a preclinical antibody‑drug conjugate from Aimedbio that targets proteins expressed broadly in solid tumors, in a deal valued at up to roughly $991 million. The asset—designed to address KRAS‑mutant and other hard‑to‑treat tumors—will move into a planned Phase I study next year under the partnership. Aimedbio retains upside via milestone and royalty provisions while Boehringer gains development and commercialization rights across specified indications. The transaction underscores continued big‑pharma interest in externalizing ADC pipelines via asset deals that de‑risk early development.